Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Reporting date: October 4, 2022. This Current Report was filed under Item 8.01 in anticipation of the company filing one or more registration statements on Form S-3.
Business Context and Reporting Period
The filing recasts selected financial information and related disclosures from the company’s 2021 Form 10-K for the year ended December 31, 2021. The revisions reflect a change in reportable segments first reported in the company’s first-quarter 2022 Form 10-Q.
Ginkgo now reports two segments: Foundry and Biosecurity, replacing the historical single-segment presentation. The recast presentation is consistent with the company’s subsequent quarterly filings for the quarters ended March 31 and June 30, 2022.
Financial Metrics and Liquidity
This Form 8-K does not provide a clear standalone update to revenue, profit, cash flow, margins, debt, liquidity, or other current-period financial metrics. Exhibit 99.1 contains revised excerpts from the 2021 Form 10-K, including Management’s Discussion and Analysis and financial statements, but the filing text provided does not include the underlying numerical details.
Material Changes Versus the Prior Comparable Period
- The material change is the revised classification and presentation of historical results into the Foundry and Biosecurity reportable segments.
- The filing does not state that the underlying historical financial results were changed; it states that the presentation was revised to reflect the new segment structure.
- No portions of the 2021 Form 10-K other than Part II, Item 7 and Part II, Item 8 are being updated by this Form 8-K.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no new financial guidance or operating outlook. It states that the recast information generally remains stated as of December 31, 2021 and does not reflect subsequent information or events other than the segment-presentation changes. Investors are directed to later SEC filings for subsequent developments.
The recast information is intended for incorporation by reference into future Securities Act filings, including anticipated Form S-3 registration statements. Exhibits include the independent registered public accounting firm’s consent, the revised 2021 Form 10-K excerpts, and the Inline XBRL cover page file.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the recast Foundry and Biosecurity historical revenue, expenses, assets, and other segment disclosures.
- Confirm that the revised presentation is consistent with the segment reporting in the March 31 and June 30, 2022 Form 10-Q filings.
- Review subsequent SEC filings for financial results, liquidity, financing activity, guidance, and events occurring after December 31, 2021.
- Assess any future Form S-3 registration statements and related securities offerings for potential dilution, use of proceeds, and financing risks.